Entrada Therapeutics, Inc.
$6.58
-0.90%Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.9).
Valuation inputs: P/E -1.9, earnings yield N/A, momentum -0.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -47.0%, ROIC -43.7%).
Profitability stack: net margin -5.7%, ROE -47.0%, ROIC -43.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +18.9%, momentum -0.9%, net margin -5.7%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Entrada Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Entrada Therapeutics, Inc. Fair Value Envelope
Entrada Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Entrada Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Entrada Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Entrada Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that TRDA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 10.00 to a high of 21.00.
The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 10.00 to a high of 21.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Entrada Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $990K and sold $5.40M worth of TRDA shares, resulting in $4.41M of net selling activity.
3 Months
5.0K
29.32K
74.9K
1.07M
-1.0M
-$1.04M
3-6 Months
0
0.00
8.0K
97.89K
-98K
-$98K
6-9 Months
24.6K
210.12K
408.9K
3.61M
-3.4M
-$3.40M
9-12 Months
95.0K
750.50K
92.1K
625.10K
+125K
+$125K
Top Buyers
Baker Bros. Advisors Lp
10 Percent Owner
$210K
Zeiher Bernhardt G
Director
$179K
Kim Peter S
Director
$150K
Thistle Mary
Director
$150K
Chapman Gina
Director
$150K
Top Sellers
Parmar Kush
Director, 10 Percent Owner:
$2.03M
5Am Ventures V, L.P.
10 Percent Owner
$2.03M
Wentworth Kory James
Officer: Chief Financial Officer
$443K
Dowden Nathan J
Officer: President & Coo
$435K
Sethuraman Natarajan
Officer: President, Research & Develop.
$408K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $4.41M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
TRDA has not reported any dividend yield values in the available annual periods.
trda Dividend History
Learning Layer
Related Guides
Build conviction on TRDA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.